ClinicalTrials.gg
CompletedNCT03340142Updated Nov 15, 2018

VIVO™ Accuracy Study

An interventional study of VIVO™ in Premature Ventricular Contraction and Ventricular Tachycardia, sponsored by Catheter Precision. Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-15.

Sponsored by Catheter Precision. Inc. · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was Sep 2018, 8 years 2 months ago, and no results have been posted to the registry.
Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

A multi-center study designed to assess the accuracy of VIVO™ in determining the location of a PVC/VT foci in comparison to an electroanatomical mapping system.

Read the detailed description

The VIVO accuracy study will assess the accuracy of locating a PVC/VT foci by pacing known anatomical locations and comparing the VIVO outcome to that of the Carto system (Biosense-Webster).

02

Conditions studied

  • Premature Ventricular Contraction
  • Ventricular Tachycardia
03

In context

Ventricular Premature Complexes

102 studies on the registry are indexed under Ventricular Premature Complexes; 32 are open to participants now.

This study's enrollment of 45 is below the median of 84 across 58 interventional studies indexed under Ventricular Premature Complexes.

Browse Ventricular Premature Complexes studies →

Lead sponsor

Catheter Precision. Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who are at least 18 years or older
  • Subjects who are scheduled for PVC/VT ablation procedure with structurally normal hearts and less than 10% scar.
  • Subjects who have signed an IRB/EC approved Form and applicable subject privacy protection authorization per local law
  • Subjects will be selected without regard to gender or age (unless precluded by local regulatory requirements)

Exclusion criteria

Exclusion Criteria:

  • Subjects who are for CT or MRI (must be able to get one)
  • Subject whose MRI or CT scan does not comply with the requirements of this protocol
  • Subjects who are contraindicated for an electrophysiology procedure and/or fluoroscopy:
  • > 3
  • Active infection
  • Pregnancy: Females of with a positive pregnancy test.
  • Existing mechanical heart valve
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Single Arm

    All patients will undergo standard of care ablation procedures. VIVO™ results will be compared to that of standard of care results, but will not be used in diagnosis or treatment.

    Device: VIVO™

Interventions

  • DeviceVIVO™

    Diagnose the area of a PVC or VT onset

06

What researchers measure

Primary outcomes

  1. Accuracy of correctly identifying PVC or VT origin

    Determine the accuracy of VIVO in identifying a PVC/VT to the left or right ventricle or the septum. The origin, identified by VIVO, will be compared to the Carto system and the successful ablation location.

    Time frame: 1 Day

Secondary outcomes

  1. Accuracy of correctly identifying known pacing sites

    Determine the accuracy of VIVO in identifying the location of known pacing sites as compared to the Carto system. The origin, identified by VIVO, will be compared to the location identified by Carto as well as the successful ablation location.

    Time frame: 1 Day

  2. Number of adverse events

    Monitor adverse events that occur during the procedure followed by a review from the CEC for correlation to VIVO and adjudication if appropriate.

    Time frame: 1 Day

07

Study locations

3 sites
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Johns Hopkins Unveristy
    Baltimore, Maryland 21287, United States
  • Medical Unversity of South Carolina
    Charleston, South Carolina 29425, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03340142
Lead sponsor
Catheter Precision. Inc.
Responsible party
Sponsor
First posted
Nov 13, 2017
Start date
Jan 29, 2018
Primary completion
Sep 4, 2018
Completion
Nov 1, 2018
Last update
Nov 15, 2018

Study contacts

Missiaen Huck
study director · Catheter Precision. Inc.

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion